Question 1

What is Kexing Biopharm?

Accepted Answer

Kexing Biopharm is a Company.

Question 2

How often does Kexing Biopharm appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 7 articles.

Question 3

When was Kexing Biopharm first tracked by Ergen?

Accepted Answer

First tracked on Jun 04, 2026.

Question 4

When was Kexing Biopharm last mentioned in news?

Accepted Answer

Last active on Jun 04, 2026.

Question 5

What is Kexing Biopharm's current news sentiment?

Accepted Answer

Aggregate sentiment score: 70 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Kexing Biopharm in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving Kexing Biopharm?

Accepted Answer

Kexing Biopharm GB10 Phase I Trial (Jun 04, 2026, 7 articles).

Question 8

How did the "Kexing Biopharm GB10 Phase I Trial" event impact Kexing Biopharm?

Accepted Answer

Kexing Biopharm is the parent company whose subsidiary, Shenzhen Kexing Pharmaceutical Co., Ltd., developed GB10 Injection. This event marks a significant milestone in its innovative drug R&D pipeline, potentially expanding its global footprint and driving internationalization.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.